Report Detail
Global Blood Cancer Drugs Market Insights, Forecast to 2025
- RnM2708128 |
- 06 May, 2019 |
- Global |
- 118 Pages |
- QYResearch |
- Pharma & Healthcare
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
The global Blood Cancer Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of 10.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Blood Cancer Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Blood Cancer Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Blood Cancer Drugs in these regions.
This research report categorizes the global Blood Cancer Drugs market by top players/brands, region, type and end user. This report also studies the global Blood Cancer Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Market size by Product
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Market size by End User
Leukemia
lymphoma
Multiple Myeloma
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Blood Cancer Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Blood Cancer Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Blood Cancer Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Blood Cancer Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Blood Cancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Blood Cancer Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Blood Cancer Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Blood Cancer Drugs Market Size Growth Rate by Product
- 1.4.2 Blood Chemotherapy Drugs
- 1.4.3 Blood Targeted Therapy Drugs
- 1.5 Market by End User
- 1.5.1 Global Blood Cancer Drugs Market Size Growth Rate by End User
- 1.5.2 Leukemia
- 1.5.3 lymphoma
- 1.5.4 Multiple Myeloma
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Blood Cancer Drugs Market Size
- 2.1.1 Global Blood Cancer Drugs Revenue 2014-2025
- 2.1.2 Global Blood Cancer Drugs Sales 2014-2025
- 2.2 Blood Cancer Drugs Growth Rate by Regions
- 2.2.1 Global Blood Cancer Drugs Sales by Regions
- 2.2.2 Global Blood Cancer Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Blood Cancer Drugs Sales by Manufacturers
- 3.1.1 Blood Cancer Drugs Sales by Manufacturers
- 3.1.2 Blood Cancer Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Blood Cancer Drugs Revenue by Manufacturers
- 3.2.1 Blood Cancer Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Blood Cancer Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Blood Cancer Drugs Price by Manufacturers
- 3.4 Blood Cancer Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Blood Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Blood Cancer Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Blood Cancer Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Blood Cancer Drugs Sales by Product
- 4.2 Global Blood Cancer Drugs Revenue by Product
- 4.3 Blood Cancer Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Blood Cancer Drugs Breakdown Data by End User
6 North America
- 6.1 North America Blood Cancer Drugs by Countries
- 6.1.1 North America Blood Cancer Drugs Sales by Countries
- 6.1.2 North America Blood Cancer Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Blood Cancer Drugs by Product
- 6.3 North America Blood Cancer Drugs by End User
7 Europe
- 7.1 Europe Blood Cancer Drugs by Countries
- 7.1.1 Europe Blood Cancer Drugs Sales by Countries
- 7.1.2 Europe Blood Cancer Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Blood Cancer Drugs by Product
- 7.3 Europe Blood Cancer Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Blood Cancer Drugs by Countries
- 8.1.1 Asia Pacific Blood Cancer Drugs Sales by Countries
- 8.1.2 Asia Pacific Blood Cancer Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Blood Cancer Drugs by Product
- 8.3 Asia Pacific Blood Cancer Drugs by End User
9 Central & South America
- 9.1 Central & South America Blood Cancer Drugs by Countries
- 9.1.1 Central & South America Blood Cancer Drugs Sales by Countries
- 9.1.2 Central & South America Blood Cancer Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Blood Cancer Drugs by Product
- 9.3 Central & South America Blood Cancer Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Blood Cancer Drugs by Countries
- 10.1.1 Middle East and Africa Blood Cancer Drugs Sales by Countries
- 10.1.2 Middle East and Africa Blood Cancer Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Blood Cancer Drugs by Product
- 10.3 Middle East and Africa Blood Cancer Drugs by End User
11 Company Profiles
- 11.1 Amgen,
- 11.1.1 Amgen, Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Amgen, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Amgen, Blood Cancer Drugs Products Offered
- 11.1.5 Amgen, Recent Development
- 11.2 AstraZeneca PLC,
- 11.2.1 AstraZeneca PLC, Company Details
- 11.2.2 Company Business Overview
- 11.2.3 AstraZeneca PLC, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 AstraZeneca PLC, Blood Cancer Drugs Products Offered
- 11.2.5 AstraZeneca PLC, Recent Development
- 11.3 Astellas Pharma,
- 11.3.1 Astellas Pharma, Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Astellas Pharma, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Astellas Pharma, Blood Cancer Drugs Products Offered
- 11.3.5 Astellas Pharma, Recent Development
- 11.4 Bayer AG,
- 11.4.1 Bayer AG, Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bayer AG, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bayer AG, Blood Cancer Drugs Products Offered
- 11.4.5 Bayer AG, Recent Development
- 11.5 Bristol-Myers Squibb Company,
- 11.5.1 Bristol-Myers Squibb Company, Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Products Offered
- 11.5.5 Bristol-Myers Squibb Company, Recent Development
- 11.6 Celgene Corporation,
- 11.6.1 Celgene Corporation, Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Celgene Corporation, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Celgene Corporation, Blood Cancer Drugs Products Offered
- 11.6.5 Celgene Corporation, Recent Development
- 11.7 Eli Lilly,
- 11.7.1 Eli Lilly, Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Eli Lilly, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Eli Lilly, Blood Cancer Drugs Products Offered
- 11.7.5 Eli Lilly, Recent Development
- 11.8 F.Hoffmann-La Roche,
- 11.8.1 F.Hoffmann-La Roche, Company Details
- 11.8.2 Company Business Overview
- 11.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 F.Hoffmann-La Roche, Blood Cancer Drugs Products Offered
- 11.8.5 F.Hoffmann-La Roche, Recent Development
- 11.9 Johnson & Johnson,
- 11.9.1 Johnson & Johnson, Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Johnson & Johnson, Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Johnson & Johnson, Blood Cancer Drugs Products Offered
- 11.9.5 Johnson & Johnson, Recent Development
- 11.10 Novartis
- 11.10.1 Novartis Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Novartis Blood Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Novartis Blood Cancer Drugs Products Offered
- 11.10.5 Novartis Recent Development
- 11.11 Pfizer,
- 11.12 Takeda Pharmaceutical Company Ltd,
- 11.13 AbbVie
12 Future Forecast
- 12.1 Blood Cancer Drugs Market Forecast by Regions
- 12.1.1 Global Blood Cancer Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Blood Cancer Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Blood Cancer Drugs Market Forecast by Product
- 12.2.1 Global Blood Cancer Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Blood Cancer Drugs Revenue Forecast by Product 2019-2025
- 12.3 Blood Cancer Drugs Market Forecast by End User
- 12.4 North America Blood Cancer Drugs Forecast
- 12.5 Europe Blood Cancer Drugs Forecast
- 12.6 Asia Pacific Blood Cancer Drugs Forecast
- 12.7 Central & South America Blood Cancer Drugs Forecast
- 12.8 Middle East and Africa Blood Cancer Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Blood Cancer Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Blood Cancer Drugs . Industry analysis & Market Report on Blood Cancer Drugs is a syndicated market report, published as Global Blood Cancer Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Blood Cancer Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
